Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing

AIDS

Volumn 23, Issue 10, 2009, Pages 1209-1218

  Archer, John ^a   Braverman, Michael S ^b   Taillon, Bruce E ^b   Desany, Brian ^b   James, Ian ^c   Harrigan, P Richard ^d   Lewis, Marilyn ^c   Robertson, David L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b 454 Life Sciences ^*  (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

AIDS; Chemokine (c c motif) receptor 5 (ccr5); Chemokine (cxc motif) receptor 4 (cxcr4); Chemokine receptors; Coreceptors; HIV; Maraviroc; Pyrosequencing

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CXCR4; ENVELOPE PROTEIN; MARAVIROC;

ANTIVIRAL RESISTANCE; ARTICLE; DRUG TREATMENT FAILURE; ENTROPY; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ALIGNMENT;

CYCLOHEXANES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; PHYLOGENY; RECEPTORS, CXCR4; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TRIAZOLES;

EID: 67651055421     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832b4399     Document Type: Article

References (34)

1. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum antihuman immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-4732.
2. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-1441.
3. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist mar- aviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006;80:4909-4920.
4. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, Wrin T, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007;51:566-575.
5. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991;253:71-74.
6. ShiodaT, LevyJA, Cheng-MayerC. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992; 89:9434-9438.
7. Pollakis G, Abebe A, Kliphuis A, Chalaby MI, Bakker M, Mengistu Y, et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004;78:2841-2852.
8. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, He HX, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77:13376-13388.
9. Pillai S, Good B, Richman D, Corbeil J. Anew perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 2003; 19:145-149.
10. Rosen O, Sharon M, Quadt-AkabayovSR, AnglisterJ. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Proc Natl Acad Sci USA 2006;103:13950-13955.
11. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses 2007; 23:415-426.
12. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994; 68:4400-4408.
13. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
14. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999;179:254-258.
15. Shankarappa R, MargolickJB, GangeSJ, Rodrigo AG, Upchurch D, Farzadegan H, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-10502.
16. Low AJ, Dong W, Chan D, Sing T, Swanstrom R, Jensen M, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. Aids 2007;21: F17-F24.
17. Margulies M, Egholm M, Altman WE, AttiyaS, BaderJS, Bemben LA, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437:376-380.
18. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrose- quencing: application to HIV-1 drug resistance. Genome Res 2007;17:1195- 1201.
19. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363, 365.
20. Brockman W, Alvarez P, Young S, Garber M, Giannoukos G, Lee WL, et al. Quality scores and SNP detection in sequencing- by-synthesis systems. Genome Res 2008; 18:763-770.
21. Pop M, Salzberg SL. Bioinformatics challenges of new sequencing technology. Trends Genet 2008; 24:142-149.
22. Trombetti GA, Bonnal RJ, Rizzi E, De Bellis G, Milanesi L. Data handling strategies for high throughput pyrosequencers. BMC Bioinformatics 2007;8 (Suppl 1):S22.
23. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005;11:1170-1172.
24. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25:3389-3402.
25. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32: 1792-1797.
26. Durbin R, Eddy S, Krogh A, Mitchison G. Biological sequence analysis: probabilistic models of proteins and nucleic acids. Cambridge University Press; 1998.
27. Smith TF, Waterman MS. Identification of common molecular subsequences. J Mol Biol 1981;147:195-197.
28. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 2003;52:696-704.
29. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, Mullins JI. Consensus and ancestral state HIV vaccines. Science 2003;299:1515-1518;author reply 1515-1518.
30. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25:4876-4882.
31. Lewis M, Simpson P, Fransen S, Huang W, Whitcomb J, Mosley M, et al. CXCR4-using virus detected in patients receiving maraviroc in the Phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antiviral Ther 2007;12:S65-S165.
32. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinfor- matics prediction of HIV coreceptor usage. Nat Biotechnol 2007;25:1407-1410.
33. Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, et al. Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol 2008; 82:5584-5593.
34. PastoreC, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of- fitness mutations. J Virol 2006;80:750-758.